Characteristics of indirect pharmacodynamic models and applications to clinical drug responses

British Journal of Clinical Pharmacology

Volumn 45, Issue 3, 1998, Pages 229-239

  Sharma, Amarnath ^a,b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Indirect response models; Pharmacodynamics

Indexed keywords

ALPHA2A INTERFERON; CIMETIDINE; FLUTICASONE PROPIONATE; FUROSEMIDE; IBUPROFEN; METHYLPREDNISOLONE; NIZATIDINE; PREDNISOLONE; PYRIDOSTIGMINE; TERBUTALINE; TOLRESTAT; WARFARIN;

DOSE RESPONSE; DRUG RESPONSE; HUMAN; MODEL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; STOMACH ACID SECRETION; THEORY;

HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY;

EID: 0031890386     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00676.x     Document Type: Review

References (32)

1. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokin 1981; 6: 429-453.
2. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-371.
3. Ariens EJ. In Molecular Pharmacology: The mode of action of biologically active compounds. Vol. 1, ed Ariens EJ, New York: Academic Press, 1964.
4. Nagashima R, O'Reilly RA, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfirm. Clin Pharmacol Ther 1969; 10: 22-35.
5. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-478.
6. Sharma A, Jusko VJ. Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1996; 24: 611-634.
7. Callaghan JT, Bergstrom RF, Obermeyer BD, et al. Intravenous nizatidine kinetics and acid suppression. Clin Pharmacol Ther 1985; 37: 162-15.
8. Nieforth KA, Nadeau R, Patel IH, et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996; 59: 636-646.
9. Lew KH, Ludwig EA, Milad MA, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 402-414.
10. Rohatagi S, Bye A, Mackie AE, et al. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci 1996; 4: 341-350.
11. Rohatagi S, Bye A, Falcoz C, et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996; 36: 938-941.
12. Francheteau P, Steimer, J-L, Dubray C, et al. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922. J Pharmacokinet Biopharm 1991; 19: 287-309.
13. Ekblad EBM, Licko V. A model eliciting transient responses. Am J Physiol 1984; 246: R114-R121.
14. Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra and interindividual aspects. J Pharmacol Exp Ther 1995; 274: 921-927.
15. Sharma A, Jusko WJ. Indirect pharmacodynamic models for tolerance and rebound phenomena. IBC Library Series 1997; Southborough, MA.
16. Wakelkamp M, Alvan G, Gabrielsson J, et al. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996; 60: 75-88.
17. Van Griensven JMT, Jusko WJ, Lemkes HHPJ, et al. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers alld patients with insulin-dependent diabetes. Clin Pharmacol Ther 1995; 58: 631-640.
18. Pitsiu M, Parker EM, Aarons L, et al. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults. Eur J Pharm Sci 1993; 1: 151-157.
19. Milad MA, Ludwig EA, Anne S, et al. Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J Pharmacokinet Biopharm 1994; 22: 469-480.
20. Yamamoto K, Abe M, Katashima M, et al. Pharmacodynamic analysis of antiplatelet effect of aspirin in the literature-modeling based on inhibition of cyclooxygenase in the platelet and the vessel wall endothelium. J Jpn J Hosp Pharm 1996; 22: 133-141.
21. Jusko WJ. Pharmacodynamics of chemotherapeutic effects: Dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 1971; 60: 892-895.
22. Zhi J, Nightingale CH, Quintilliani R. Microbial pharmacodynamics of piperacillin in neutropenic mice of systemic infection due to pseudomonas aeruginosa. J Pharmacokinet Biopharm 1988; 16: 355-375.
23. Xu Z-X, Sun Y-N, DuBois DC, et al. Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm 1995; 23: 163-181.
24. Jusko WJ, Ko HC, Ebling WF. Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 1995; 23: 5-8.
25. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22: 69-74.
26. Brater DC. Pharmacodynamic consideration in use of diuretics. Ann Rev Pharmacol Toxicol 1983; 23: 45-62.
27. Fisher LE, Ludwig EA, Jusko WJ. Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm 1992; 20: 319-331.
28. Garg V, Jusko WJ. Pharmacodynamic modeling of nonsteroidal anti-inflammatory agents: antipyretic effect of ibuprofen. Clin Pharmacol Ther 1994; 55: 87-88.
29. Ko HC, Jusko WJ. Pharmacodynamic modeling of finasteride, a 5α-reductase inhibitor. Pharmacotherapy 1995; 15: 509-511.
30. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmaol Ther 1994; 56: 406-419.
31. Xu Z-X, Lee M-J, Blum RA, Jusko WJ. Pharmacodynamic modeling of prednisolone effects on natural killer cell trafficking. Pharm Res 1994; 11: 848-854.
32. Wald JA, Jusko WJ. Corticosteroid phamacodynamic modeling: Osteocalcin suppression by prednisolone. Pharm Res 1992; 9: 1096-1098.